Sandoz has signed a global collaboration agreement with Shanghai Henlius Biotech to commercialize a biosimilar of oncology therapy, ipilimumab (Bristol-Myers Squibb’s Yervoy). The agreement is ...

LONDON (Reuters) -The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide list price for new medicines is "deeply flawed" and ...

Under the terms of the agreement, Sandoz has exclusive commercial rights for a biosimilar of ipilimumab in Australia, Canada, Europe, Japan and the US. The core sequence patent for ipilimumab ...

LONDON, April 28 (Reuters) - The chief executive of generic drugmaker Sandoz (SDZ.S), opens new tab said a proposal by the CEOs of Novartis (NOVN.S), opens new tab and Sanofi (SASY.PA), opens new ...

Richard Saynor, Chief Executive Officer of Sandoz, commented: “With Q1 sales in line with our expectations, we have now delivered fourteen consecutive quarters of top-line growth. This ...

ZURICH (Reuters) -Swiss generic drug manufacturer Sandoz (SIX:SDZ) said on Monday it had filed an antitrust lawsuit in the United States against Amgen (NASDAQ:AMGN) over the alleged entrenchment ...

Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for treatment of variety of cancer types, targeting net reference medicine sales of USD 2.5 billion[1] Henlius to develop and ...

Investing.com -- Sandoz (SIX:SDZ) shares slid around 3% Wednesday after the Swiss drugmaker reported first-quarter 2025 sales that came in 5% below company-compiled consensus. Excluding the impact ...

LONDON (Reuters) -The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide list price for new medicines is "deeply flawed" and ...

It is the powerful combination of delivery and pioneering access for patients that makes us proud to be part of the Sandoz growth journey.” This guidance excludes any impacts of unforeseen events or ...